Vicapsys is focused on leveraging natural pathways in a localized manner in order to achieve beneficial therapies without systemic negative consequences. At the core of Vicapsys technology is a pleiotropic cytokine, CXCL12 that can be optimally formulated to achieve therapeutic outcomes in different indications. Vicapsys is currently focused on curing Type 1 diabetes through long-term survival of transplanted islet cells using a formulation that inhibits development of the foreign body response and immune protection. Vicapsys is also leveraging its core technology to address the consequences of diabetes (diabetic foot ulcers) and the consequences of localized fibrosis (abdominal adhesions).